Takeda Places Focus on Personalized Care and Innovation for Bleeding Disorders at ISTH 2022
Takeda Places Focus on Personalized Care and Innovation for Bleeding Disorders at ISTH 2022
- 13 Abstracts Across Takeda’s Hematology Portfolio and Pipeline, Including Two Studies that Explore the Potential Benefits of Prophylaxis in Patients with von Willebrand Disease (VWD)
- Eight-Year Readout from the International AHEAD Study, a Real-World Study Evaluating Long-Term Outcomes in Patients with Severe/Moderate Hemophilia A
- Thrombotic Thrombocytopenic Purpura (TTP) Abstract Highlights Need for More Robust, Comprehensive Epidemiological Data to Understand Global Impact of Disease.
CAMBRIDGE, Mass. & OSAKA, Japan, July 11, 2022 – Takeda (TSE: 4502/NYSE:TAK) will present 13 abstracts at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2022, spanning the company’s extensive existing hematology portfolio, and R&D pipeline. The data have the potential to drive advances in personalized care for people living with Hemophilia A and von Willebrand disease (VWD), while also highlighting the need for more research to help understand the global impact of rare thrombotic disorders such as thrombotic thrombocytopenic purpura (TTP).
“The breadth of data we are presenting across our established portfolio and our pipeline is evidence of our resolve to continually improve the standard of care in and raise disease awareness for bleeding and thrombotic disorders,” said Daniel Curran, M.D., Head, Rare Genetics & Hematology Therapeutic Area Unit at Takeda. “As a patient-driven, science-first organization, we advocate for an individualized approach to treatment: one which acknowledges that each patient’s experience of the disease is unique to them. Several abstracts presented at ISTH add to the growing body of evidence supporting the potential benefits for prophylaxis in VWD and Hemophilia A. In addition, data that are being presented from a systematic review on the epidemiology of TTP further highlights our commitment to facilitating understanding, education, and awareness of rare blood diseases.”
Takeda is spotlighting data from two studies that explore the potential benefits of prophylaxis when pursuing a patient-centric, individualized approach to treating von Willebrand disease (VWD). Two studies, a post-hoc analysis of a European socio-economic study and a retrospective US cohort study, examined the effects of prophylaxis on disease burden in patients receiving prophylaxis compared to those who were eligible but not currently receiving prophylaxis. 1,2
An eight-year interim readout from the Antihemophilic factor (recombinant) (rAHF) Hemophilia A outcome Database (AHEAD) – a real-world study evaluating outcomes in patients with severe or moderate Hemophilia A – will be featured as an oral presentation.3 The session will discuss data on the impact of pharmacokinetic-guided prophylaxis with FVIII on bleed rates and joint health compared to on-demand treatment.
Takeda is committed to raising disease awareness and elevating the understanding of rare bleeding and thrombotic disorders. As such, Takeda will present data from a systematic review on the worldwide epidemiology of TTP. This poster presentation highlights the need for more comprehensive, robust data to help understand disease demography and worldwide impact.4
A full list of abstracts Takeda is presenting can be found here: https://www.isth2022.org/program.
About Takeda Hematology
Takeda is a leader in bleeding disorders with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real-world experience. We have 70+ years driving innovation for patients and a broad portfolio of products across multiple bleeding disorders. Our experience as a leader in hematology means we are well prepared to meet today’s needs as we pursue future developments in the care of blood disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
U.S. and International Media
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”,
“should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
- ISTH 2022. Abstract [PB0825] Burden of Illness in Patients With von Willebrand Disease Receiving Prophylaxis Versus Potential Prophylaxis-Eligible Patients: A Post-Hoc Analysis of A European Socioeconomic Study
- ISTH 2022. Abstract [PB0824] Characteristics and Clinical Burden Among Patients With von Willebrand Disease Eligible for Prophylaxis: Results From a Retrospective US Cohort Study
- ISTH 2022. Abstract [OC 27.2] Clinical Outcomes Following Prophylaxis With Octocog Alfa in Patients With Moderate Hemophilia A: 8-Year Interim Read-out of the Real-world AHEAD International Study
- ISTH 2022. Abstract [PB0298] A Systematic Review of the Current Epidemiology of Immune-Mediated and Congenital Thrombotic Thrombocytopenic Purpura caused by Severe ADAMTS13 Deficiencies.